Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (322)	2/13/1999 1:57:00 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 626

Now we know that insiders are buying the stock, as the current issue of Barron's indicates that two(2) insiders have bought 105,272 shares of TTP. This represents a 715% increase in their holdings. In the weekly chart that Barron's provides for insider buy/selling, TTP is shown as the #1 stock because of this percentage increase. Actually, if you got back and look from December of 1998 there is massive insider buying in this stock. Lindsay Rosenwald has bought well over 100,000 shares in several transactions.

To: scaram(o)uche who wrote (322)	2/13/1999 2:09:00 PM
From: NeuroInvestment	Read Replies (1) \| Respond to of 626

Rick: Nice pickup on this citation, as a hypothesis for atypical drug effects on so-called negative symptoms, and supporting iloperidone's effects therein. Obliquely off topic, it also adds to one's interest in the Gliatech H3 program--while I have yet to be all that impressed with atypical antipsychotics so far as upregulating cognition in sz is concerned, they have a lot of 'noise' built in via their other multiple receptor effects, and the disorder itself. A pure H3 antagonist working in a 'pure' cognitive enhancement paradigm could be very intriguing. NeuroInvestment (www.neuroinvestment.com)